Are ultrasensitive ctDNA assays ready for clinical use in early-stage NSCLC?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 41386218.
- Also identified by DOI 10.1016/j.cell.2025.11.021.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Disease recurrence in early-stage non-small cell lung cancer (NSCLC) remains a persistent clinical challenge, underscoring the need for better prognostic biomarkers. In this preview, we highlight the clinical implications of ultrasensitive ctDNA monitoring in lung cancer risk modeling reported by Black et al. in this issue of Cell.
Medical subject headings
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
- Circulating Tumor DNA